Zogenix Provides Business Update SAN DIEGO, Jan. 12, 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zogenix Provides Business Update

SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX ), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position.

Business Update:

  • Acquired Brabant Pharma on October 24, 2014, obtaining global rights for an orphan drug in development for the treatment of Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy.
     
  • Total prescriptions for Zohydro ER in the fourth quarter 2014 were approximately 19,000, a 26% increase compared to the third quarter 2014 1 .
     
  • Secured a $20 million term loan and a $4 million revolving line of credit in December 2014.
     
  • Preliminary unaudited cash and cash equivalents as of December 31, 2014 were approximately $42.2 million. This includes $21.5 million in cash from the term loan and revolving line of credit secured in December 2014. An additional $8.5 million is being held in escrow from the proceeds of the sale of Sumavel DosePro to Endo Pharmaceuticals in May 2014.

Roger Hawley, chief executive officer of Zogenix, stated, "During the fourth quarter we continued to drive adoption of Zohydro ER, with positive feedback on product efficacy from physicians and patients. Entering 2015, we believe we are in a good position to further expand adoption of Zohydro ER with the potential U.S. Food and Drug Administration's approval and launch of a formulation with abuse deterrent properties and the potential addition of a co-promotion partner."

Mr. Hawley added, "We have several important clinical activities related to our new product pipeline planned for 2015. The multi-dose clinical trial for Relday will commence in January, with results expected to be available during the third quarter. In addition, we are preparing to begin enrollment in the Phase 3 clinical trial for ZX008 in the third quarter, a major milestone for our orphan drug product candidate for the treatment of Dravet syndrome that we acquired from Brabant Pharma in October 2014."

The preliminary unaudited cash position discussed above is subject to the completion of financial closing procedures and other developments that may arise between now and the time the financial results for the fourth quarter are finalized, as well as the completion of the audit of the 2014 financial statements. Therefore, actual results may differ materially from these estimates. In addition, the above estimates do not present all information necessary for an understanding of Zogenix's financial condition as of December 31, 2014. Zogenix expects to report full financial results for the fourth quarter and full year ended December 31, 2014 in early March 2015.

About Zogenix

Zogenix, Inc. (Nasdaq: ZGNX ) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "plans," "expects," "will," "potential" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding Zogenix's cash position as of December 31, 2014, the expected timing of the FDA approval and the commercial launch of a Zohydro ER formulation with abuse deterrent properties, continued adoption of Zohydro ER and the potential to add a co-promotion partner, and the timing of the commencement of clinical trials for Relday and ZX008. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: risks related to changes in estimated financial amounts based on the completion of financial closing procedures and the audit of the financial statements; Zogenix's dependence on the successful commercialization of Zohydro ER; Zogenix's ability to achieve broad market acceptance and generate revenues from sales of Zohydro ER; difficulties or delays relating to the development, testing, manufacturing and marketing of and obtaining regulatory approval for an abuse deterrent formulation of Zohydro ER or any of Zogenix's other product candidates; Zogenix's dependence on third parties to develop an additional formulation of Zohydro ER, Relday and ZX008; public concern regarding the safety of drug products such as Zohydro ER and the impact of negative publicity and political influences relating to the regulation of the pain management market in general and opioids and Zohydro ER in particular; difficulties in identifying, negotiating and carrying out a co-promotions agreement for Zohydro ER; and other risks described in the company's prior press releases and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Zohydro® ER is a registered trademark of Zogenix, Inc.

1 Symphony Health Solutions, Source® PHAST Prescription Weekly, February 2014 – December 2014

Investors Zack Kubow, The Ruth Group 646.536.7020,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading